Karen Ballen headshot

Karen Kuhn Ballen

Unit: School of Medicine
Department: Department of Medicine, Hematology and Oncology
Office location and address
Emily Couric Clinical Cancer Center
1335 Lee St
Charlottesville, Virginia 22903
Dartmouth Medical School, MD

Dr. Karen Ballen is a professor of medicine at UVA School of Medicine. She also serves as section chief of hematologic malignancies and stem cell transplants. 

Dr. Ballen received her undergraduate degree in history and literature from Harvard College and her doctorate from Dartmouth Medical School. She completed her medical residency at Beth Israel Hospital and a hematology/oncology fellowship at Brigham and Women’s Hospital, both in Boston, MA. Before joining UVA's faculty in 2017, Dr. Ballen was the director of the Leukemia Program at Massachusetts General Hospital and a professor of medicine at Harvard Medical School.

Dr. Ballen’s research interests are in novel therapeutic strategies for acute leukemia, including immunotherapy and targeted agents. She is an international expert in stem cell transplants, particularly for patients who have a difficult time finding a donor. Dr. Ballen started one of the first cord blood banks in the Unites States, and she has published over 150 articles on transplants and acute leukemia. She is on the advisory committee of the Center for International Blood and Marrow Transplant Research and the chair of the cord blood advisory committee for the National Marrow Donor Program. 

In her spare time, Dr. Ballen likes to hike. She and her daughter climbed Mount Kilimanjaro in 2016.

Ballen BMT CTN 1506
Source: National Marrow Donor Program
May 02, 2018 – May 01, 2023
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (CTRL-ALT-D) BMT CTN Protocol #1702
Source: National Marrow Donor Program
August 06, 2019 – August 05, 2022
MD-INMD-HO - Ballen - Bioniz - BNZ1-CT-201
Source: Bioniz Therapeutics, Inc.
February 15, 2018 – February 14, 2022
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relpased or Refractory DIffuse Large B-cell Lymphoma of the Activated B-cell subtype
Source: Alliance for Clinical Trials in Oncology Foundatio
May 15, 2017 – June 01, 2021